About Peony Glycoside (from Paeonia lactiflora)
Paeoniflorin is the primary active glycoside of white/red peony root (Paeonia lactiflora), most often studied as part of standardized 'total glucosides of paeony' (TGP) extract. Multiple RCTs and meta-analyses support TGP as an adjunctive anti-inflammatory/immunomodulatory agent in rheumatoid arthritis and other autoimmune-rheumatic conditions, typically alongside conventional therapy, with benefits emerging over 1-6 months. Evidence for isolated paeoniflorin outside this TGP/rheumatologic context (e.g., skin, mood) is preclinical only.
What Peony Glycoside (from Paeonia lactiflora) supports
- May reduce disease activity as an add-on therapy in rheumatoid arthritis/autoimmune conditions — supported by multiple RCTs and meta-analyses of standardized peony extract (TGP)
How much Peony Glycoside (from Paeonia lactiflora) to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
600–1200
mg
Range reflects RCT dosing of standardized total glucosides of paeony (TGP) extract, of which paeoniflorin is the principal marker compound — not a dose of isolated paeoniflorin itself, which labels rarely disclose separately.
Clinical evidence
Moderate clinical evidence. Multiple RCTs/meta-analyses support TGP (paeoniflorin-standardized) as adjunctive rheumatologic therapy; evidence for other uses is preclinical.
NIH Fact Sheet